Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

45.16USD
7 Dec 2018
Change (% chg)

$0.31 (+0.69%)
Prev Close
$44.85
Open
$45.08
Day's High
$46.82
Day's Low
$44.49
Volume
5,219
Avg. Vol
22,232
52-wk High
$68.91
52-wk Low
$36.66

Latest Key Developments (Source: Significant Developments)

Urogen Pharma Ltd Files For Mixed Shelf Of Upto $250 Million
Friday, 12 Oct 2018 05:32pm EDT 

Oct 12 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA LTD FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.  Full Article

Urogen Pharma Submits Investigational New Drug Application For UGN-102 For The Treatment Of LG NMIBC
Wednesday, 11 Jul 2018 08:00am EDT 

July 11 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR UGN-102 (VESIGEL™) FOR THE TREATMENT OF LOW-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (LG NMIBC).UROGEN PHARMA LTD - IF ACCEPTED, COMPANY EXPECTS TO BEGIN A PHASE 2B CLINICAL TRIAL IN UNITED STATES IN Q3 2018.  Full Article

Urogen Pharma Reports Q4 Loss Per Share Of $0.74
Thursday, 15 Mar 2018 07:00am EDT 

March 15 (Reuters) - Urogen Pharma Ltd ::UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.74.Q4 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.‍TOP-LINE DATA FROM OLYMPUS PIVOTAL TRIAL ARE EXPECTED IN Q3 2018.​.‍POTENTIAL APPROVAL AND COMMERCIAL LAUNCH OF MITOGEL IN UNITED STATES IS TARGETED FOR H2 2019​.‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALED $73.0 MILLION​.‍ ASSUMING POSITIVE RESULTS, PLANNED SUBMISSION OF NDA TO U.S. FDA IN Q1 2019 FOR MITOGEL​.  Full Article

Urogen Announces Proposed Public Offering Of Ordinary Shares
Tuesday, 16 Jan 2018 04:04pm EST 

Jan 16 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES.UROGEN PHARMA SAYS IT HAS FILED WITH U.S. SEC IN CONNECTION WITH A PUBLIC OFFERING OF 1.1 MILLION ORDINARY SHARES.  Full Article

Urogen Pharma Q3 loss per share $0.02
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Urogen Pharma Ltd :Urogen Pharma reports third quarter 2017 financial results and recent corporate developments.Q3 loss per share $0.02.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​
Wednesday, 8 Nov 2017 09:02am EST 

Nov 8 (Reuters) - UroGen Pharma Ltd -:Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​.  Full Article

Urogen Pharma receives FDA fast track designation for Mitogel
Tuesday, 29 Aug 2017 08:30am EDT 

Aug 29 (Reuters) - Urogen Pharma Ltd :Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC).Mitogel currently being evaluated in ongoing pivotal phase 3 olympus clinical trial in patients with low-grade UTUC.  Full Article

UroGen Pharma Q2 loss per share $0.70
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Urogen Pharma Ltd :UroGen Pharma reports second quarter 2017 financial results and recent corporate developments.Q2 loss per share $0.70.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma
Thursday, 20 Jul 2017 04:55pm EDT 

July 20 (Reuters) - Urogen Pharma Ltd :Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing.  Full Article

Allergan submits investigational NDA for rtgel in combination with botox
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Urogen Pharma Ltd ::Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan.Says it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with allergan.Urogen Pharma - milestone payment resulting from Allergan's submission of investigational new drug application for rtgel in combination with botox to U.S. FDA.  Full Article

Photo

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.